Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2

STATEMENT OF NEED

Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of treatment planning (Gegenback et al, 2021). Therapeutic options for relapsed/refractory multiple myeloma are rapidly changing with evolving data, making it difficult for clinicians to stay abreast of the latest advances in multiple myeloma treatment (i3 Health, 2021). In this webinar, Sarah Holstein, MD, PhD, and Ashley Rosko, MD, will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how their approaches to relapsed/refractory multiple myeloma are changing based on emerging data.

TARGET AUDIENCE

Hematologists, oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with multiple myeloma (MM).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Differentiate biochemical versus clinical relapse and indications for the treatment of multiple myeloma progression
Appraise emerging efficacy and safety data on novel combination therapies for early relapse in patients with multiple myeloma
Appraise emerging efficacy and safety data on novel combination therapies for late relapse in patients with multiple myeloma